



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☐ Declaration Submitted with Initial Filing
OR
☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number 631020.90015

First Named Inventor Martin G. Sirois

COMPLETE IF KNOWN

Application Number 09 / 945,131

Filing Date August 31, 2001

Group Art Unit 1635

Examiner Name

RECEIVED
APR 28 2003
TECH CENTER 1600/2900

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

LOCALIZED OLIGONUCLEOTIDE THERAPY FOR PREVENTING RESTENOSIS

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) August 31, 2001 as United States Application Number or PCT International

Application Number 09/945,131 and was amended on (MM/DD/YYYY) n/a (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
n/a			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

14-04-03 08:18 De-GOUDREAU GAGE DUBUC

+1-514-387-4382

E-540 P.03/04 Trav232

Please type a plus sign (+) inside this.

APR 28 2003

PTO/BA01 (10-03)

Approved for use through 10/31/2003. OMB 0851-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

Direct all correspondence to:		<input checked="" type="checkbox"/> Customer Number or Bar Code Label	26718	OR	<input type="checkbox"/> Correspondence address below
Name					
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.					
NAME OF SOLE OR FIRST INVENTOR:				<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname		Birth	
Martin G.					
Inventor's Signature				Date	
Residence: City		State		Country	
Montreal		Quebec		Canada	
Mailing Address 5800 Belanger Street					
Mailing Address					
City		State		Country	
Montreal		Quebec		Canada	
NAME OF SECOND INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle (if any))		Family Name or Surname		Birth	
Eliaser R.		Edelman			
Inventor's Signature				Date	
<i>Eliaser R. Edelman</i>				4-14-03	
Residence: City		State		Country	
Brookline		MA		USA	
Mailing Address 30 Warren St.					
Mailing Address					
City		State		Country	
Brookline		MA		USA	
<input checked="" type="checkbox"/> Additional inventors are being named on _____ supplemental Additional Inventor(s) sheet(s) PTO/CB/02A attached hereto.					

(Page 2 of 2)



I hereby certify that this correspondence is being deposited with the United States Postal Services on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.
Date of Signature and Deposit: 6/2/01 John C. Baker
Attorney of Record

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Martin G. Sirois, et al.
Serial No.: 09/241,561
Filed: February 1, 1999
For: LOCALIZED OLIGONUCLEOTIDES THERAPY
FOR PREVENTING RESTENOSIS
Group Art Unit: 1635
Examiner: A. Wang

DECLARATION UNDER 37 CFR 1.132

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

1. Martin G. Sirois, Michael Simons and Elazer R. Edelman are three of the named inventors in the above-identified patent application and are also the authors of Sirois, et al., Circulation 95(3) (February 4, 1997)..

2. Inventor Robert D. Rosenberg was not an author on the Sirois, et al. paper because he did not contribute to the drafting of that paper. However, Inventor Rosenberg contributed to the idea that is presented in the paper and in the specification, and that is claimed in the above-referenced application.

3. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like made are punishable by fine or imprisonment, or both, under

RECEIVED
APR 30 2003
TECH CENTER 1600/2900

Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the above-identified application or any patent issuing thereon.

Respectfully submitted,

June 5, 2001
Date

Martin G. Sirois
Martin G. Sirois